Caixin Global – Latest China News & Headlines

Home >


CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

India Ban Could Hit TikTok’s Parent Company to the Tune of $6 Billion
Meituan Eyes Robot-Enabled Deliveries with $14 Million Investment in PuduTech
Sina Weibo to Issue $750 Million in Bonds
Trending in China: Shenzhen Thinks Only Children Should Get Paid Leave to Look After Their Parents - Cue Heated Debate
German Drugmaker BI Launches Shanghai Center to Harness Chinese Expertise
Chinese Self-Driving Truck Firm Aims to Cover Most of U.S. by 2024
Trending in China: Chinese Netizens Tell Indian Prime Minister Modi To ‘Shut The Door On The Way Out’ As He Quits Weibo
Trending in China: If You Can’t Beat Them, Join Them – Why Tencent is Laughing At Itself
Meituan Eyes Robot-Enabled Deliveries with $14 Million Investment in PuduTech
India Ban Could Hit TikTok’s Parent Company to the Tune of $6 Billion
Sina Weibo to Issue $750 Million in Bonds
Embattled Leshi Forced to Sell Smart TV, Livestreaming Trademarks and Swiss Cleaning Carmaker Launch Driverless Street Sweeper
Trending in China: How an ‘Old Godmother’ Took on China’s Internet Giant and Won
China’s IT Spending Expected to Hit $297 Billion: IDC
TikTok Moves Data Protection of European Users from U.S. to U.K. and Ireland
Trending in China: Dazed and Confused – China’s Elderly in Online Pandemic World
Alibaba-Owned Taobao Live Sacks Former Operating Head for Corruption
Tesla Supplier CATL Breaks Ground With New Battery Lab
Chinese Online Educator Zuoyebang Receives $750 Million Investment
Didi to Halt Service in Several Japanese Prefectures Citing Impact of Covid-19
Trending in China: ‘Robotaxis’ A Brave New World or Creating More Unemployment?
Lazada Appoints Former Alibaba Executive as New CEO
China Approves New Rheumatoid Arthritis Drug

By Zhao Runhua and Di Ning / Jul 24, 2019 04:53 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Another global pharmaceutical company won government approval to sell a drug to sufferers of rheumatoid arthritis (RA) in China after multiple international companies announced approvals to offer treatments to millions of patients.

Belgium-based UCB was cleared to provide treatment for moderate-to-severe RA patients with Cimzia, a drug the company submitted in 2018 to China’s National Medical Product Administration for review, according to an official release. UCB said Cimzia is its first biologic therapy approved for the China market. The treatment is widely used for cancer and other conditions to restore patients’ immune systems. 

RA is a chronic illness in which a patient’s immune system causes pain by attacking joints. The cause remains unknown. According to a report published by the Chinese Medical Association’s RA group, the Chinese mainland now has around 5 million RA patients.

The effective date and pricing for Cimzia’s sales in China were not available.

An RA drug co-developed by Lilly and Incyte won approval from the Chinese government earlier this month. A Lilly spokesperson told Caixin the price would be decided with careful consideration of Chinese patients’ purchasing capability. Lilly also said it hoped China’s national medical insurance program could support patients’ use of the drug.

Contact reporter Zhao Runhua (

Share this article
Open WeChat and scan the QR code